About iosBio: Revolutionising Global Vaccination

Our mission is to develop and deliver innovative oral, thermostable vaccines for major infectious diseases using our proprietary technology platforms.

We combine cutting-edge science in virology, immunology, and formulation with advanced technologies like Enhanced Surface Display (ESD™) and AI-driven antigen design to create vaccines that offer significant advantages over traditional methods.

Our Experienced Leadership Team

iosBio is led by a dedicated team with extensive experience in biotechnology, vaccine development, clinical trials, business development, and finance.

Wayne Channon
(Exec Chairman)

Wayne is a successful entrepreneur with experience of managing high growth companies from start-up to exit and IPO…

Dr Elliot Bland
(COO)

Elliot is a fellow of Queen Mary University of London, where he held responsibility for commercialisation of life-science projects, non-clinical regulatory packages…

Dr Craig Laferrière
(CDO)

Craig joined iosBio from CANVAX, Novateur Ventures Inc., an international vaccine consulting business…

Ben Warriner
(Financial Advisor)

Ben is a highly experienced finance professional with more than a decade of international leadership experience working within the healthcare sector…

Peter Cozens PhD
Non-Executive Director

Peter has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry…

James Hudleston
Non-Executive Director

James is an entrepreneur, corporate financier and highly successful investor in technology, biotechnology and the resource sector

Myra Waiman
Non-Executive Director

Myra is a biochemist and worked in hospitals for a number of years before establishing Romney Consultants as a strategy and business consultancy…

Follow us

Keep up to date with our news and find out more about investment opportunities with iosBio.

The team of doctors and scientists at iosBio believe that the next great leap forward in immunization will be oral delivery

Enabling the fastest and most cost-effective deployment of vaccines the world has ever seen. This is not just a huge leap forward from a humanitarian perspective, oral vaccine technology also represents a significant commercial opportunity.

Contact us on

info@iosbio.com / 01444 241911

or fill out the form below.





    We will not, in any circumstances share your personal information with other individuals or organizations without your permission.